MCL - Section 691.1672

OPIOID LIABILITY LITIGATION ACT (EXCERPT)
Act 85 of 2022


691.1672 Definitions.

Sec. 2.

    As used in this act:
    (a) "Allergan settlement" means the master settlement agreement arising out of the MDL and entered into by this state with Allergan Pharmaceuticals.
    (b) "CVS settlement" means the master settlement agreement arising out of the MDL and entered into by this state with CVS Pharmacy.
    (c) "Distributor settlement" means the master settlement agreement arising out of the MDL and entered into by this state with AmerisourceBergen Corporation, Cardinal Health, Inc., and McKesson Corporation.
    (d) "Janssen settlement" means the master settlement agreement arising out of the MDL and entered into by this state with Janssen Pharmaceuticals, Inc.
    (e) "MDL" means In re Nat'l Prescription Opiate Litigation, multidistrict litigation consolidated in the United States District Court for the Northern District of Ohio, Case No. 1:17-MD-2804.
    (f) "Political subdivision" means a public body corporate in this state, an agency of a public body corporate in this state, a nonincorporated body in this state of whatever nature, or an agency of a nonincorporated body in this state. Political subdivision includes a county, city, village, township, school district, or special district or authority of this state. Political subdivision does not include this state.
    (g) "Teva settlement" means the master settlement agreement arising out of the MDL and entered into by this state with Teva Pharmaceuticals.
    (h) "Walgreens national settlement" means the master settlement agreement arising out of the MDL and entered into by this state with Walgreens Pharmacy.
    (i) "Walmart settlement" means the master settlement agreement arising out of the MDL and entered into by this state with Walmart.
    
    


History: 2022, Act 85, Imd. Eff. May 19, 2022 ;-- Am. 2023, Act. 228, Imd. Eff. Nov. 22, 2023